Transcriptomic analysis of VK12653 Multiple Myeloma bone marrow microenvironmentupon treatment with anti-CD137 agonists

We report the RNA sequencing of VK12653 Multiple Myeloma bone marrow microenvironment upon treatment with anti-CD137 agonists Overall design: A global transcriptomic analysis of BM cells isolated from WT mice challenged with Vk12653 myeloma cells (2.106 cells, i.v) treated or not with anti-CD137 mAb (10 µg; 3H3, i.p twice a week) was performed by RNAseq using TruSeq Stranded mRNA Sample Preparation kit on a Novaseq 6000 S4 Illumina sequencing platform generating in average 20 million pairs of reads per sample.

本研究报道了经抗CD137激动剂处理后，VK12653多发性骨髓瘤（Multiple Myeloma）骨髓微环境的RNA测序分析结果。整体实验设计如下：本研究通过尾静脉（intravenous, i.v.）注射2×10^6个VK12653骨髓瘤细胞对野生型小鼠（Wild Type, WT）进行造模，随后从造模小鼠体内分离骨髓（Bone Marrow, BM）细胞，分别对接受或未接受抗CD137单克隆抗体（anti-CD137 mAb，单克隆抗体monoclonal antibody）处理的细胞开展全局转录组分析；抗体给药方案为单次剂量10 μg的克隆号3H3抗体，每周两次腹腔注射（intraperitoneal, i.p.）。本研究采用TruSeq链特异性mRNA样本制备试剂盒（TruSeq Stranded mRNA Sample Preparation kit），在Illumina Novaseq 6000 S4测序平台上完成RNA测序（RNAseq），每个样本平均生成2000万条读段对。